### Breast Cancer

- **Triple negative breast cancer (TNBC)**
  - Locally advanced/metastatic TNBC

- **Hormone receptor positive (HR+)**
  - Locally advanced/metastatic ER+ and/or PR+/HER2
  - Locally advanced/metastatic ER+/HER2-

- **Non HER2 positive with BRCA mutation**

- **TNB or HR**
  - PTEN or PIK3CB mutation (TNBC or ER+/HER2-)
  - With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)
  - Bone metastatic breast cancer (TNBC or ER+ and/or PR+)

- **HER2 positive**
  - HER2+ PIK3CA mutation, PTEN mutation or PTEN loss

**ETCTN Trials by Disease/Treatment Area: Breast Cancer**

- **10382**: A Phase III Trial Evaluating the Safety and Efficacy of Erbitux in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer (Phase 1: limited; Phase 2: ETCTN-wide)

- **10146**: Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Neoantigen Vaccine Vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) in Patients with Metastatic Triple Negative Breast Cancer

- **9881**: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (4 cohorts: NSCLC, TNBC, PDAC, SCLC)

- **10287**: A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)

- **10195**: A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination with Fulvestrant in Women with Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor

- **10020**: A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2 Positive Breast Cancer

- **10029**: A Phase II Study of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

- **10291**: A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

- **10302**: Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

- **10146**: A Phase I Study of AZD8156 in Combination with Docetaxel in Patients with TNPT (PTB) Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Dose escalation: Solid tumors with PTEN or PIK3CB Mutations; Expansion cohorts include: breast, prostate, and other solid tumors.)

- **10129**: A Phase 1 Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

- **10302**: Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

- **10146**: A Phase II Trial of Copanlisib in Combination with Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) with PIK3CA Mutation or PTEN Mutation (Limited in phase 1 only; will open ETCTN-wide in phase 2).

**Note**: *No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: April 17, 2020*